Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.

N-Aryl aminothiazoles 6-9 were prepared from 2-bromothiazole 5 and found to be CDK inhibitors. In cells they act as potent cytotoxic agents. Selectivity for CDK1, CDK2, and CDK4 was dependent of the nature of the N-aryl group and distinct from the CDK2 selective N-acyl analogues. The N-2-pyridyl analogues 7 and 19 showed pan CDK inhibitory activity. Elaborated analogues 19 and 23 exhibited anticancer activity in mice against P388 murine leukemia. The solid-state structure of 7 bound to CDK2 shows a similar binding mode to the N-acyl analogues.

[1]  E. Sausville.  Complexities in the development of cyclin-dependent kinase inhibitor drugs. , 2002, Trends in molecular medicine.

[2]  L. Meijer,et al.  Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. , 1997, Journal of medicinal chemistry.

[3]  A. Senderowicz,et al.  Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials , 2004, Investigational New Drugs.

[4]  Punit Marathe,et al.  Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. , 2002, Journal of medicinal chemistry.

[5]  E. Sausville,et al.  Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.

[6]  A. Huwe,et al.  Small molecules as inhibitors of cyclin-dependent kinases. , 2003, Angewandte Chemie.

[7]  M. Doyle,et al.  Alkyl Nitrite-Metal Halide Deamination Reactions. 2. Substitutive Deamination of Arylamines by Alkyl Nitrites and Copper(II) Halides. A Direct and Remarkably Efficient Conversion of Arylamines to Aryl Halides , 1977 .

[8]  E. Sausville,et al.  Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development , 2002, The Annals of pharmacotherapy.

[9]  K. Webster,et al.  The therapeutic potential of targeting the cell cycle. , 1998, Expert opinion on investigational drugs.

[10]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[11]  K. Webster,et al.  Novel drugs targeting the cell cycle , 2000 .

[12]  E. Schierenberg,et al.  Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases , 1995, Biology of the cell.

[13]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[14]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[15]  E. Sausville,et al.  Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. , 1996, International journal of oncology.

[16]  P. Ponath.  Chemokine receptor antagonists: novel therapeutics for inflammation and AIDS. , 1998, Expert opinion on investigational drugs.

[17]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[18]  Punit Marathe,et al.  N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. , 2004, Journal of medicinal chemistry.

[19]  K. Webster,et al.  Chapter 14. Cell cycle kinases and checkpoint regulation in cancer , 2001 .

[20]  E. Vokes,et al.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. D. Harris,et al.  Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). , 1996, The Journal of organic chemistry.